Hormone Refractory Prostate Cancer
Conditions
Keywords
Adenocarcinoma, Prostatic Neoplasms, Carcinoma, Prostatic Diseases
Brief summary
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
Interventions
None listed
Sponsors
The First Affiliated Hospital of Zhengzhou University
the cancer hospital of Zhengzhou University
People's Hospital of Zhengzhou University
Xinyang Central Hospital
Zhoukou Central Hospital
the second people's hospital of kaifeng
Zhengzhou University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Healthy volunteers
No
Inclusion criteria
1. Eligible patients had histologically or cytologically confirmed adenocarcinoma of the prostate with clinical or radiologic evidence of disease progression during hormonal therapy 2. Patients were receiving primary androgen-ablation therapy as maintenance therapy. At least four weeks had to have elapsed between the withdrawal of antiandrogens (six weeks in the case of bicalutamide) and enroll ment, so as to avoid the possibility of confounding as a result of the response to antiandrogen withdrawal. 3. Another requirement was disease progression, as indicated by increasing serum levels of PSA on three consecutive measurements obtained at least one week apart or findings on physical examination or imaging studies. 4. Normal cardiac function was required.
Exclusion criteria
1. patients had a Karnofsky performance-status score of at most 60 percent 2. prior treatment with cytotoxic agents or radioisotopes 3. with history of another cancer within the preceding five years, brain or leptomeningeal metastases, symptomatic peripheral neuropathy of grade 2 or higher, and other serious medical condition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | From the date of biochemical or clinical recurrence of prostate cancer following hormonal therapy to December 31, 2016 or date of death from any cause, whichever came first, assessed up to 3 years. |
Secondary
| Measure | Time frame |
|---|---|
| prostate cancer specific mortality | From the date of biochemical or clinical recurrence of prostate cancer following hormonal therapy to December 31, 2016 or death from prostate cancer or treatment complications, whichever came first, assessed up to 3 years. |
Countries
China
Contacts
Primary ContactLiu Bingqian, MD Ph.D
Outcome results
None listed